市場調查報告書
商品編碼
1380448
2023-2030 年全球臨床前影像市場Global Preclinical Imaging Market 2023-2030 |
全球臨床前影像市場預計在預測期(2023-2030年)CAGR為6.82%。市場的成長歸因於靈敏度和解析度的提高。高場 MRI 系統提高了掃描的靈敏度和解析度,使研究人員能夠檢測和分析動物模型中微妙的結構和功能修飾。這種更高水平的靈敏度和解析度對於準確建模疾病和評估潛在候選藥物非常重要。因此,市場參與者正在推出新產品來滿足新 MRI 設備的需求。例如,2022年5月,布魯克推出了創新的磁振造影(MRI)設備,包括7.4特斯拉和9.4特斯拉傳導冷卻麥克斯韋磁體,構成其市場領先的臨床前MRI系統產品線的組成部分。 BioSpec Maxwell 3 Tesla 模型取得了巨大成功,由於新一代 Maxwell 7.4 Tesla 和 9.4 Tesla 磁鐵,液體不再是必需品。同時為創新的 PET/MR 和 MRI 臨床前研究提供高場靈敏度和氮氣或氦氣填充解析度。
全球臨床前成像市場按產品、應用和最終用戶進行細分。根據產品,市場細分為 MicroCT、MRI、PET、超音波成像、光學成像、光聲成像等。根據應用,市場細分為製藥和生物技術公司、研發、神經病學和神經科學等。此外,根據最終用戶,市場細分為製藥和生物技術公司、學術和研究機構、醫院和醫療中心、政府研究機構等。該製藥和生物技術公司的子類別預計將佔據最終用戶細分市場的很大一部分市場佔有率。這是由於傳染病的發展和重新出現、對臨床前成像的需求以增強對病原體的理解並鼓勵創新療法和疫苗的創造。
其中,超音波成像細分市場預計將在全球臨床前成像市場中佔據相當大的佔有率。細分市場的成長歸因於技術的創新。由於超音波和光聲成像等成像技術的進步,研究人員能夠探索新的臨床前研究方向,從而導致使用量的增加。因此,市場參與者正在推出新產品,以滿足臨床前使用超音波和光聲成像系統的需求。例如,2022年5月,FUJIFILM VisualSonics Inc.推出了全球首款臨床前使用的超高低頻(71MHz-1MHz)超音波和光聲成像系統Vevo F2。 Vevo F2 產生從感測器到顯示器的全新訊號管道,並包含高畫質影像處理技術。與多線處理相結合,它提高了影像清晰度,並導致比前幾代平台顯著更高的幀速率。
全球臨床前影像市場根據地理位置進一步細分,包括北美(美國和加拿大)、歐洲(英國、義大利、西班牙、德國、法國和歐洲其他地區)、亞太地區(印度、中國、日本) 、韓國和亞洲其他地區)以及世界其他地區(中東和非洲以及拉丁美洲)。其中,預計亞太地區將在全球市場中佔據顯著佔有率,因為由於政府加大對各國研發部門成長的支持,該地區越來越需要臨床前研究。
在所有地區中,北美地區預計在預測期內將以相當大的CAGR成長。區域成長歸因於該地區醫療保健的擴張。隨著醫療保健服務的成長,全球對先進影像技術(尤其是臨床前影像)的需求預計將增加。根據美國勞工統計局的數據,2023 年 9 月,放射線和 MRI 技術人員的總就業人數預計在 2022 年至 2032 年間將成長 6%,快於所有職業的平均水準。未來十年,預計放射學和 MRI 技術人員的職缺平均為 15,700 個。預計替換因退休而改變職業或離開勞動力隊伍的工人的需求將導致大部分可用職位空缺。
服務全球臨床前影像市場的主要公司包括: Bruker Corp.、Euro-BioImaging ERIC、FUJIFILM Holdings Corp.、IVIM Technology Corp.、Mediso Kft.。和別的。市場參與者透過各種策略(包括併購、合作、合作、融資和新產品發布),為市場成長做出了巨大貢獻,以保持市場競爭力。例如,2019年5月,布魯克不斷合作開發了第一台18特斯拉、11公分孔徑、臨床前超高場(UHF)MRI機器。
Title: Global Preclinical Imaging Market Size, Share & Trends Analysis Report by Product (MicroCT (Micro Computed Tomography), MRI (Magnetic Resonance Imaging), PET (Positron Emission Tomography), Ultrasound Imaging, Optical Imaging, Photoacoustic Imaging, and Others), by Application (Pharma and Biotech Companies, Research and Development, Neurology and Neuroscience, and Others), and by End-User (Pharma and Biotech Companies, Academic and Research Institutions, Hospitals and Medical Centers, Government Research Agencies, and Others)Forecast Period (2023-2030).
The global preclinical imaging market is anticipated to grow at a CAGR of 6.82% during the Forecast Period (2023-2030). The market's growth is attributed to enhancement of sensitivity and resolution. High-field MRI systems improve the sensitivity and resolution of scans, enabling researchers to detect and analyze delicate structural and functional modifications in animal models. This higher level of sensitivity and resolution is important for accurately modeling diseases and evaluating potential drug candidates. Accordingly market players are coming up with new products to cater the demand for new MRI devices. For instance, in May 2022,Bruker launched innovative magnetic resonance imaging (MRI) devices, including 7.4 Tesla and 9.4 Tesla conduction-cooled Maxwell magnets, form a component of its product line of market-leading preclinical MRI systems. The BioSpec Maxwell 3 Tesla model was an enormous success, and the Liquid is ceased to essential owing to a new generation of Maxwell 7.4 Tesla and 9.4 Tesla magnets. while providing high-field sensitivity and nitrogen or helium refills resolution for innovative PET/MR and MRI preclinical research.
The global preclinical imaging market is segmented on the product, application, and end-user. Based on the product, the market is sub-segmented into MicroCT, MRI, PET, ultrasound imaging, optical imaging, photoacoustic imaging, and others. Based on the application, the market is sub-segmented into pharma and biotech companies, research and development, neurology and neuroscience, and others. Furthermore, on the basis of end-user, the market is sub-segmented into pharma and biotech companies, academic and research institutions, hospitals and medical centers, government research agencies, and others. The pharma and biotech company's subcategory is expected to capture a significant portion of the market share within the end-user segment. This is attributed to the development and reemergence of infectious diseases, the demand for preclinical imaging for enhanced comprehension of pathogens and encourage the creation of innovative therapies and vaccines.
Among the product, the ultrasound imaging sub-segment is expected to hold a considerable share of the global preclinical imaging market. The segmental growth is attributed to the innovation in technology. Increased usage results from the ability of researchers to explore new preclinical research directions owing to advancements in imaging technologies such as ultrasound and photoacoustic imaging. Accordingly market players are coming up with new products to cater the demand for ultrasound and photoacoustic imaging system designed for preclinical use. For instance, in May 2022,FUJIFILM VisualSonics Inc., launched Vevo F2, the globe's first ultra-high to low frequency (71MHz-1MHz) ultrasound and photoacoustic imaging system for preclinical use. The Vevo F2 produces entire new signal pipeline, from transducer to display screen, and includes HD image processing technologies. In combination with multi-line processing, it improves image clarity and results in significantly higher frame rates than platforms from preceding generations.
The global preclinical imaging market is further segmented based on geography including North America (the US, and Canada), Europe (UK, Italy, Spain, Germany, France, and the Rest of Europe), Asia-Pacific (India, China, Japan, South Korea, and Rest of Asia), and the Rest of the World (the Middle East & Africa, and Latin America). Among these, Asia-Pacific is anticipated to hold a prominent share of the market across the globe, as the region has grown increasingly desirable for preclinical research studies owing to increased government support for the growth of the research and development sector in the individual countries.
Among all regions, the North America regions is anticipated to grow at a considerable CAGR over the forecast period. Regional growth is attributed to the expansion of healthcare in the region. Global demand for advanced imaging technologies, especially preclinical imaging, is anticipated to increase as healthcare services grow. According to the US Bureau of Labor Statistics, in September 2023, Radiologic and MRI technologists' total employment is anticipated to increase by 6% between 2022 and 2032, faster than the average for all occupations. Over the next ten years, there are anticipated to be, on average, 15,700 openings for radiologic and MRI technologists. The need to replace workers that change careers or leave the workforce owing to retirement is predicted to cause a large portion of the available openings.
The major companies serving the global preclinical imaging market include: Bruker Corp., Euro-BioImaging ERIC, FUJIFILM Holdings Corp., IVIM Technology Corp., Mediso Kft. and others. The market players are considerably contributing to the market growth by the adoption of various strategies including mergers and acquisitions, partnerships, collaborations, funding, and new product launches, to stay competitive in the market. For instance, in May 2019, Bruker collaborated to develop the first 18 Tesla, 11 cm bore, preclinical ultra-high field (UHF) MRI machine constantly.